Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2021 10/13/2021 10/14/2021 10/15/2021 10/18/2021 Date
14.71(c) 14.99(c) 15.45(c) 15.13(c) 14.92 Last
2 193 994 2 521 433 2 703 517 1 969 946 3 064 143 Volume
+2.01% +1.90% +3.07% -2.07% -1.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 155 M - -
Net income 2021 -210 M - -
Net Debt 2021 29,1 M - -
P/E ratio 2021 -12,7x
Yield 2021 -
Sales 2022 235 M - -
Net income 2022 -152 M - -
Net cash position 2022 7,44 M - -
P/E ratio 2022 -19,2x
Yield 2022 -
Capitalization 2 669 M 2 669 M -
EV / Sales 2021 17,4x
EV / Sales 2022 11,3x
Nbr of Employees 246
Free-Float 99,1%
More Financials
Company
BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and... 
More about the company
Ratings of BioCryst Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about BIOCRYST PHARMACEUTICALS, INC.
10/05BIOCRYST PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
10/04BIOCRYST PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/21BIOCRYST PHARMACEUTICALS : to Present at 2021 Cantor Virtual Healthcare Conference
AQ
09/20BIOCRYST PHARMACEUTICALS : Appoints Dr. Amy McKee to Board of Directors (Form 8-K)
PU
09/20BIOCRYST PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statem..
AQ
09/20BioCryst Appoints Dr. Amy McKee to Board of Directors
GL
09/20BioCryst Pharmaceuticals, Inc. Appoints Amy McKee to Its Board of Directors
CI
09/16BIOCRYST PHARMACEUTICALS : NICE Recommends BioCryst's ORLADEYO (berotralstat), the First O..
AQ
09/16BIOCRYST PHARMACEUTICALS : Scores UK Regulatory Recommendation for Hereditary Angioedema D..
MT
09/15BIOCRYST PHARMACEUTICALS : NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First ..
AQ
09/15NICE Recommends Biocryst’s Orladeyo® (Berotralstat), the First Oral, Once-Daily Therapy..
CI
09/15Health Care Stocks Pare Early Gains As Cyclicals Dominate Afternoon Trade
MT
09/14INSIDER SELL : Biocryst Pharmaceuticals
MT
09/10BIOCRYST PHARMACEUTICALS : Announces Approval of ORLADEYO (berotralstat) in United Arab Em..
AQ
09/09BIOCRYST PHARMACEUTICALS' : Orladeyo Receives Marketing Authorization in UAE; Shares Down ..
MT
More news
News in other languages on BIOCRYST PHARMACEUTICALS, INC.
09/16BioCryst obtient la recommandation des autorités réglementaires britanniques pour son m..
09/15Les actions du secteur de la santé réduisent leurs gains initiaux alors que les produit..
09/14VENTE D'INITIÉS : Biocryst Pharmaceuticals
09/09Orladeyo de BioCryst Pharmaceuticals reçoit l'autorisation de mise sur le marché aux Ém..
09/01Les actions du secteur de la santé inversent leurs pertes alors que les biotechnologies..
More news
Analyst Recommendations on BIOCRYST PHARMACEUTICALS, INC.
More recommendations
Chart BIOCRYST PHARMACEUTICALS, INC.
Duration : Period :
BioCryst Pharmaceuticals, Inc. Technical Analysis Chart | BCRX | US09058V1035 | MarketScreener
Technical analysis trends BIOCRYST PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 14,92 $
Average target price 21,27 $
Spread / Average Target 42,6%
EPS Revisions
Managers and Directors
Jon P. Stonehouse President, Chief Executive Officer & Director
Michael L. Jones Executive Director-Finance
Anthony Doyle Chief Financial Officer, Treasurer & Senior VP
Robert Alexander Ingram Chairman
William P. Sheridan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BIOCRYST PHARMACEUTICALS, INC.103.09%2 706
GILEAD SCIENCES, INC.16.08%84 795
BIONTECH SE203.83%59 820
WUXI APPTEC CO., LTD.28.00%57 897
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156